Scholar Rock Holding Co. (NASDAQ:SRRK) Given Consensus Rating of “Buy” by Brokerages

Scholar Rock Holding Co. (NASDAQ:SRRK) has earned a consensus rating of “Buy” from the seven brokerages that are covering the company, Marketbeat.com reports. Six investment analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $26.43.

Several equities analysts have weighed in on the company. BMO Capital Markets lifted their target price on Scholar Rock from $31.00 to $34.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. HC Wainwright reissued a “buy” rating and issued a $30.00 price target on shares of Scholar Rock in a research report on Tuesday, June 25th. Finally, Wedbush restated an “outperform” rating and set a $23.00 target price on shares of Scholar Rock in a research note on Thursday, August 8th.

Scholar Rock Stock Performance

Shares of NASDAQ SRRK opened at $8.27 on Thursday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 6.04 and a current ratio of 6.04. The stock has a fifty day moving average price of $8.94 and a two-hundred day moving average price of $11.34. Scholar Rock has a 1 year low of $6.03 and a 1 year high of $21.17. The firm has a market cap of $659.57 million, a P/E ratio of -3.96 and a beta of 0.82.

Scholar Rock (NASDAQ:SRRK) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.60) earnings per share for the quarter, topping the consensus estimate of ($0.61) by $0.01. During the same period in the prior year, the business earned ($0.47) EPS. Research analysts forecast that Scholar Rock will post -2.39 EPS for the current fiscal year.

Hedge Funds Weigh In On Scholar Rock

Large investors have recently modified their holdings of the stock. Swiss National Bank boosted its stake in Scholar Rock by 17.3% during the 4th quarter. Swiss National Bank now owns 98,100 shares of the company’s stock worth $1,844,000 after acquiring an additional 14,500 shares during the last quarter. Amalgamated Bank increased its position in shares of Scholar Rock by 15.5% in the 4th quarter. Amalgamated Bank now owns 4,869 shares of the company’s stock valued at $92,000 after buying an additional 652 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Scholar Rock by 30.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 394,138 shares of the company’s stock worth $7,410,000 after acquiring an additional 91,754 shares in the last quarter. BNP Paribas Financial Markets grew its stake in Scholar Rock by 616.8% in the fourth quarter. BNP Paribas Financial Markets now owns 48,372 shares of the company’s stock valued at $909,000 after acquiring an additional 41,624 shares during the period. Finally, Trexquant Investment LP acquired a new position in shares of Scholar Rock in the fourth quarter valued at approximately $1,359,000. 91.08% of the stock is currently owned by institutional investors and hedge funds.

About Scholar Rock

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.